PDS Biotechnology Corp
For the period ended Mar 31, 2024. Filed May 15, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2024 · Filed May 15, 2024
PDSB$1.03-4.6%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 1. Condensed Consolidated Balance Sheets
Balance Sheets
| March 31, 2024 | December 31, 2023 | |
|---|---|---|
| ASSETS · (unaudited) | ||
| Current assets: | ||
| Cash and cash equivalents | $66,634,417 | $56,560,517 |
| Prepaid expenses and other assets | 2,051,348 | 2,494,558 |
| Total current assets | 68,685,765 | 59,055,075 |
| Property and equipment, net | 129,398 | 134,132 |
| Financing lease right-to-use assets | 191,203 | 200,873 |
| Total assets | $69,006,366 | $59,390,080 |
| LIABILITIES AND STOCKHOLDERS’ EQUITY | ||
| Current liabilities: | ||
| Accounts payable | $6,000,831 | $6,982,824 |
| Accrued expenses | 1,714,111 | 2,424,692 |
| Note payable - short term | 7,291,667 | 4,166,667 |
| Financing lease obligation-short term | 57,081 | 55,794 |
| Total current liabilities | 15,063,690 | 13,629,977 |
| Noncurrent liabilities: | ||
| Note payable, net of debt discount | 16,651,420 | 19,506,183 |
| Financing lease obligation-long term | 108,211 | 122,973 |
| Total liabilities: | $31,823,321 | $33,259,133 |
| STOCKHOLDERS’ EQUITY | ||
| Common stock, $0.00033 par value, 75,000,000 shares authorized at March 31, 2024 and December 31, 2023, 36,679,275 shares and 33,094,521 shares issued and outstanding at March 31, 2024 and December 31, 2023, respectively | 12,104 | 10,921 |
| Additional paid-in capital | 192,275,033 | 170,620,641 |
| Accumulated deficit | (155,104,092) | (144,500,615) |
| Total stockholders’ equity | 37,183,045 | 26,130,947 |
| Total liabilities and stockholders’ equity | $69,006,366 | $59,390,080 |
Index
Condensed ConsolidatedStatements of Operations and Comprehensive Loss
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.